Open tender · Germany · Contract notice
Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Nadroparin (ATC-Code: B01AB06).
AOK Niedersachsen. Die Gesundheitskasse.
AOK Niedersachsen. Die Gesundheitskasse. in Germany is inviting bids for “Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Nadroparin (ATC-Code: B01AB06)”. Bids close on 27 October 2026. To qualify, bidders need at least one similar completed work and Lauer-Taxe® registration.
The work
Conclusion of a non-exclusive discount contract for the active substance Nadroparin (ATC-Code: B01AB06) under § 130a Abs. 8 SGB V in an 'open-house model'.
- Non-exclusive contract for all market participants.
- Uniform conditions for all participants.
- No individual negotiations.
Key facts
- Contract period
- Maximum 24 months from the start date.
- Evaluation
- This is a direct contract offer, not a competitive tender in the traditional sense.
What it takes to qualify
Worth a closer look
- The tender is not a public contract award in the sense of Directive 2014/24/EU, but a publication in the Supplement to the Official Journal of the European Union.
- The exact format of the 'Vertragsunterlagen' is not specified in the excerpt.
Experience
- At least 1 similar work — Experience with non-exclusive discount contracts for pharmaceuticals under § 130a SGB V.
- Experience with the 'open-house model' for contract signing.
Certifications and registrations
Lauer-Taxe® registrationContract registration in the Lauer-Taxe® is required by the AOK.
Pharmazeutischer Unternehmer i. S. d. § 4 Abs. 18 AMG§ 130a Abs. 8 SGB V requires contracts only with pharmaceutical entrepreneurs as defined by § 4 Abs. 18 AMG.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- Vertragsunterlagen (Contract documents)Submission of completed contract documents is required for participation.
- Nachweis als pharmazeutischer Unternehmer (Proof of being a pharmaceutical entrepreneur)Proof of status as a pharmaceutical entrepreneur under § 4 Abs. 18 AMG is required.